Trastuzumab deruxtecan - AstraZeneca/Daiichi Sankyo
Alternative Names: DS 8201; DS 8201a; ENHERTU; Enhertu; fam-trastuzumab deruxtecan; fam-trastuzumab deruxtecan-nxki; T-DXd; VRN-101099Latest Information Update: 09 Jul 2024
At a glance
- Originator Daiichi Sankyo Company
- Developer AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Company; Medica Scientia Innovation Research; Seagen
- Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Breast cancer; Gastric cancer; HER2 positive breast cancer; Non-small cell lung cancer
- Registered Solid tumours
- Phase II Adenocarcinoma; Biliary cancer; Colorectal cancer; Uterine cancer
- Phase I/II Urogenital cancer
Most Recent Events
- 09 Jul 2024 Updated efficacy and adverse events data from the phase III DESTINY-Breast03 trial in Breast cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 28 Jun 2024 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (IV, Infusion)
- 28 Jun 2024 No recent reports of development identified for phase-I development in Breast-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium (IV, Infusion)